New indications for biological therapies

  • Mariagrazia Catanoso
  • Nicolò Pipitone
  • Luca Magnani
  • Luigi Boiardi
  • Carlo Salvarani


Biological agents have originally been developed to treat refractory arthritis, but evidence has been accruing, supporting their use in vasculitis as well. In the large-vessel vasculitides giant cell arteritis and Takayasu arteritis, TNF-α inhibitors have shown some efficacy in patients with relapsing disease. In contrast, in patients with recent onset of giant cell arteritis, TNF-α inhibitors failed to provide a significant benefit over and above that conferred by glucocorticoids alone. More recent, preliminary data suggest a role for the interleukin-6 receptor antagonist tocilizumab in both resistant and treatment-naïve giant cell arteritis and Takayasu arteritis. Biological agents have also been proposed to treat difficult anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Uncontrolled observations suggest that the TNF-α inhibitor infliximab might be beneficial in resistant cases. On the contrary, a randomized controlled trial did not show superiority of the recombinant human soluble TNF-α p75 receptor fusion protein etanercept over placebo in maintaining remission in granulomatosis with polyangiitis. Two randomized controlled trials have demonstrated that the anti-CD20 monoclonal antibody rituximab was as effective as the standard-of-care agent cyclophosphamide in inducing remission. In addition, rituximab appeared to be superior to cyclophosphamide in inducing remission in the subset of patients with relapsing disease. These findings prove that biological therapy has a role in vasculitis. Research is investigating novel therapies as well as focusing on how to best use the available drugs.


Large vessel vasculitis ANCA-associated vasculitis Biological agents 


  1. 1.
    Salvarani C (2003) Large vessel vasculitis. Clin Exp Rheumatol 21:S133–S134PubMedGoogle Scholar
  2. 2.
    Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372:234–245PubMedCrossRefGoogle Scholar
  3. 3.
    Pipitone N, Boiardi L, Bajocchi G, Salvarani C (2006) Long-term outcome of giant cell arteritis. Clin Exp Rheumatol 24:S65–S70PubMedGoogle Scholar
  4. 4.
    Kerr GS, Hallahan CW, Giordano J et al (1994) Takayasu arteritis. Ann Intern Med 120:919–929PubMedGoogle Scholar
  5. 5.
    Pipitone N, Boiardi L, Salvarani C (2005) Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol 19:277–292PubMedCrossRefGoogle Scholar
  6. 6.
    Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49:703–708PubMedCrossRefGoogle Scholar
  7. 7.
    De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45:136–138PubMedCrossRefGoogle Scholar
  8. 8.
    Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798PubMedGoogle Scholar
  9. 9.
    Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate to treat giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789–2797PubMedCrossRefGoogle Scholar
  10. 10.
    Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582PubMedCrossRefGoogle Scholar
  11. 11.
    Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu’s arteritis and its therapy. Ann Intern Med 103:121–126PubMedGoogle Scholar
  12. 12.
    Daina E, Schieppati A, Remuzzi G (1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 130:422–426PubMedGoogle Scholar
  13. 13.
    Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M (2007) Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 26:1871–1875PubMedCrossRefGoogle Scholar
  14. 14.
    Hernandez-Rodriguez J, Segarra M, Vilardell C et al (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43:294–301CrossRefGoogle Scholar
  15. 15.
    Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford) 45:545–548CrossRefGoogle Scholar
  16. 16.
    Field M, Cook A, Gallagher G (1997) Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int 17:113–118PubMedCrossRefGoogle Scholar
  17. 17.
    Wagner AD, Wittkop U, Prahst A et al (2003) Dendritic cells co-localize with activated CD4 + T cells in giant cell arteritis. Clin Exp Rheumatol 21:185–192PubMedGoogle Scholar
  18. 18.
    Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G (2003) Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62:1116PubMedCrossRefGoogle Scholar
  19. 19.
    Uthman I, Kanj N, Atweh S (2006) Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 25:109–110PubMedCrossRefGoogle Scholar
  20. 20.
    Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630PubMedGoogle Scholar
  21. 21.
    Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630PubMedCrossRefGoogle Scholar
  22. 22.
    Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44:2933–2935PubMedCrossRefGoogle Scholar
  23. 23.
    Airo P, Antonioli CM, Vianelli M, Toniati P (2002) Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41:347–349CrossRefGoogle Scholar
  24. 24.
    Salvarani C, Macchioni P, Manzini C et al (2007) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146:631–639PubMedGoogle Scholar
  25. 25.
    Salvarani C, Cantini F, Niccoli L et al (2003) Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 30:760–763PubMedGoogle Scholar
  26. 26.
    Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C (2007) Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 57:1514–1519PubMedCrossRefGoogle Scholar
  27. 27.
    Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304PubMedCrossRefGoogle Scholar
  28. 28.
    Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567–1569PubMedCrossRefGoogle Scholar
  29. 29.
    Nordborg E, Nordborg C (1998) The inflammatory reaction in giant cell arteritis: an immunohistochemical investigation. Clin Exp Rheumatol 16:165–168PubMedGoogle Scholar
  30. 30.
    Bhatia A, Ell PJ, Edwards JC (2005) Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64:1099–1100PubMedCrossRefGoogle Scholar
  31. 31.
    Seko Y, Sato O, Takagi A et al (1996) Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu’s arteritis. Circulation 93:1788–1790PubMedGoogle Scholar
  32. 32.
    Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36:1286–1294PubMedCrossRefGoogle Scholar
  33. 33.
    Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G (1999) Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 100:55–60PubMedGoogle Scholar
  34. 34.
    Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T (2008) Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 58:1197–1200PubMedCrossRefGoogle Scholar
  35. 35.
    Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Weekly 141:13156Google Scholar
  36. 36.
    Kallenberg CGM (2011) Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 70(Suppl 1):i59–i63PubMedCrossRefGoogle Scholar
  37. 37.
    Oliver Flossmann, Annelies Berden, Kirsten de Groot et al. (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494Google Scholar
  38. 38.
    Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMedGoogle Scholar
  39. 39.
    Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis clinical and laboratory findings in eighty five patients. Arthritis Rheum 42:421–430PubMedCrossRefGoogle Scholar
  40. 40.
    Reinhold-Keller E, Beuge N, Latza U et al (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43:1021–1032PubMedCrossRefGoogle Scholar
  41. 41.
    Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with anti-neutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44PubMedCrossRefGoogle Scholar
  42. 42.
    Pagnoux C, Hogan SL, Chin H et al (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908–2918PubMedCrossRefGoogle Scholar
  43. 43.
    De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469PubMedCrossRefGoogle Scholar
  44. 44.
    Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R (1993) In situ production of TNF-, IL-1 and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 43:682–692PubMedCrossRefGoogle Scholar
  45. 45.
    Jonasdottir O, Petersen J, Bendtzen K (2001) Tumour necrosis factor-_(TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener’s granulomatosis. APMIS 109:781–786PubMedCrossRefGoogle Scholar
  46. 46.
    Lamprecht P, Voswinkel J, Lilienthal T et al (2002) Effectiveness of TNF- blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology 41:1303–1307PubMedCrossRefGoogle Scholar
  47. 47.
    Bartolucci P, Ramanoelina J, Cohen P et al (2002) Efficacy of the anti-TNF- antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41:1126–1132PubMedCrossRefGoogle Scholar
  48. 48.
    Booth AD, Jefferson HJ, Ayliffe W et al (2002) Safety and efficacy of TNF blockade in relapsing vasculitis. Ann Rheum Dis 61:559PubMedCrossRefGoogle Scholar
  49. 49.
    Booth AD, Harper L, Hammad T et al (2004) Prospective study of TNF-alpha blockade with Infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15:717–721PubMedCrossRefGoogle Scholar
  50. 50.
    Cunnane G, Doran M, Bresnihan B (2003) Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 17:345–363PubMedCrossRefGoogle Scholar
  51. 51.
    Stone JH, Uhlfelder ML, Hellmann DB et al (2001) Etanercept combined with conventional treatment in Wegener’s granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 44:1149–1154PubMedCrossRefGoogle Scholar
  52. 52.
    Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352(4):351–361CrossRefGoogle Scholar
  53. 53.
    Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 20:517–527PubMedCrossRefGoogle Scholar
  54. 54.
    Specks U, Fervenza FC, McDonald TJ, Hogan MC (2001) Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836–2840PubMedCrossRefGoogle Scholar
  55. 55.
    Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262–268PubMedCrossRefGoogle Scholar
  56. 56.
    Keogh KA, Ytterberg SR, Fervenza FC et al (2006) Rituximab for refractory Wegener’s granulomatosis: v report of a prospective, open label pilot trial. Am J Respir Crit Care Med 173:180–187PubMedCrossRefGoogle Scholar
  57. 57.
    Jones RB, Tervaert JWC, Hauser T, European Vasculitis Study Group et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220PubMedCrossRefGoogle Scholar
  58. 58.
    Stone JH, RAVE-ITN Research Group et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232PubMedCrossRefGoogle Scholar
  59. 59.
    Jones RB, Ferraro AJ, Chaudhry AN et al (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60:2156–2168Google Scholar
  60. 60.
    Specks U, Stone JH, RAVE/Immune Tolerance Network Working Group (2011) Long-term efficacy of Rituximab in ANCA-associated vasculitis. Ann Rheum Dis 70(Suppl3):85Google Scholar
  61. 61.
    Aries PM, Hellmich B, Voswinkel J et al (2006) Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853–858PubMedCrossRefGoogle Scholar
  62. 62.
    Cheung CM, Murray PI, Savage CO (2005) Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89:1542PubMedCrossRefGoogle Scholar
  63. 63.
    Omdal R, Wildhagen K, Hansen T et al (2005) Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229–232PubMedCrossRefGoogle Scholar
  64. 64.
    Freidlin J, Wong IG, Acharya N et al (2007) Rituximab treatment for peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Br J Ophthalmol 91:1414PubMedCrossRefGoogle Scholar
  65. 65.
    Taylor SRJ, Salama AD, Joshi L et al (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum 60:1540–1547Google Scholar
  66. 66.
    Guerry MJ, Brogan P, Bruce IN et al (2011) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (Epub ahead of print)Google Scholar

Copyright information

© SIMI 2011

Authors and Affiliations

  • Mariagrazia Catanoso
    • 1
  • Nicolò Pipitone
    • 1
  • Luca Magnani
    • 1
  • Luigi Boiardi
    • 1
  • Carlo Salvarani
    • 1
    • 2
  1. 1.Unità Operativa di ReumatologiaArcispedale S. Maria NuovaReggio EmiliaItaly
  2. 2.Servizio di ReumatologiaArcispedale S. Maria NuovaReggio EmiliaItaly

Personalised recommendations